Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Plexxikon
Biotech
Daiichi axes Plexxikon R&D facility to free up cash for ADC work
More than 10 years after buying the biotech for $805 million upfront, Daiichi has decided to drop the 60-employee operation to focus on ADCs.
Nick Paul Taylor
Jan 12, 2022 7:30am
Daiichi's biotech unit Plexxikon signs away BRAF cancer drug
Jun 3, 2020 10:00am
UPDATED: Daiichi’s ‘breakthrough’ PhIII trial suspended to new patients
Oct 19, 2016 4:39am